Sharon Giordano, M.D.

Sharon Giordano, M.D.

Stories this photo appears in:

Tease photo

Delaying chemotherapy in breast cancer patients reduces overall survival, especially for those with triple-negative breast cancer

MD Anderson study identifies socio-demographic factors contributing to delayed treatment

Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer (TNBC), according to a new study from The University of Texas MD Anderson Cancer Center. Further, the researchers found that factors such as socio-economic status, insurance coverage and ethnicity were associated with delayed treatment.